

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year'


November 19, 2024

Award recognizes Lisata's data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid lumors Annual BioTech Breakthrough Award is devoted to honoring excellence in life science and biotechnology solutions, services, and companies

BASKING RIDGE, NJ., Nov. 19, 2024 (GLOBE NEWSWIRE) - Lisata Therapeutics, Inc. (Nasdaq: LSTA) (or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has been selected as "Specialized BioTherapeutics Company of the Year" in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.



Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year'



SPECIALIZED BIOTHERAPEUTICS COMPANY OF THE YEAR

Lisata is recognized for its unique therapeutic approach and streamlined clinical development plans, designed to address the unmet medical needs of patients with advanced solid tumors. Through its proprietary CendR Platform® technology, which enables more effective tumor-targeted and tissue-penetrating delivery of anti-cancer drugs by activating the CendR transport mechanism, Lisata aims to improve the efficacy of existing standards-of-care and emerging anti-cancer therapies, including cytotoxics, immunotherapies, and RNA-based treatments.

By modifying the tumor microenvironment ("TME"), the Company's investigational product candidate, certepetide, reduces the immunosuppressive nature of the TME, recruits cytotoxic T cells to the tumor, and simultaneously inhibits the metastatic cascade. Certepetide has shown favorable results in enhancing the effectiveness of chemotherapy for pancreatic cancer and has received Fast Track and Orphan Drug designations from the US. Food and Drug Administration ("FDA") for the treatment of pancreatic ductal adenocarcinoma ("PDAC"), along with Orphan Drug designation for methe FDA for cholangiccarcinoma ("CCA"), and gliobalsoma multiform ("GDM"). Last has also received a Rare Policitor. Disease designation for certepetide in ostoscarcinoma ("CCA"), and

Winning the 'Specialized BioTherapeutics Company of the Year' award is a testament to Lisata's commitment to advancing the research and development of therapies to provide better outcomes for patients with solid tumors," said David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata. "Thank you to BioTech Breakthrough for this acknowledgment of the entire Lisata team and our partners. We will continue our focus on advancing our robust portfolio with the goal of bringing life-changing treatments to patients as quickly as possible."

"Lisata is continuing to transform patient lives through the discovery, development, and commercialization of innovative therapies for advanced solid tumors. The Company's novel product candidate, certepetide, is currently being evaluated in several ongoing clinical trials for the treatment of advanced solid tumors, including PDAC, CCA, GBM, colon cancer, appendiceal cancer, and melanoma," said Bryan Vaughn, Managing Director of Blochas Breakthrough. Lisata is also exploring certepetide's potential in the treatment of non-oncologic applications such as endometricois. This further demonstrates their commitment to developing curtifie-edge thereignes that address critical unmet medical needs, making them our well-deserved winnor of the Specialized BioTherapeutics Company of the Yac."

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry's most comprehensive analysis and evaluation of the world's top companies, solutions, and products in the life sciences and biotechnology markets today. This year's program attracted thousands of nominations from over 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.

About Certepetide

Certepelde is an investigational drug designed to selectively activate the C-end rule active transport mechanism in a tumor specific manner, resulting in systemically co-administered anti-cancer agents more efficiently penetrating and accumulating in the tumor. Additionally, certepelde has been shown to modify the tumor microenvironment, diminishing its immunosuppressive nature and inhibiting the metastatic cascade. Lasta and its collaborators have amassed significant non-clinical data demonstrating enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunobareples and RNA-based data, certepelde has ado demonstrate in a downood device additional data demonstrating enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, and otherapies, and and encounted and transport mechanism. The additional transport mechanism of the demotherapy for administered device additional data demonstrate in the deficientess of standard-ci-cance device additional data device additional addition in completed and onogoin clinical transport mechanism. The deficient data device administered device additional data device additional data device additional transport device additional transport device additional data device additional transport device additional data device additional transport device additional data device addite device additional d

About Lisata Therapeutics

Listat Therapeutics is a <u>clinical-stage pharmaceutical company</u> dedicated to the discovery, development and commercialization of nnovative therapies for the treatment of advanced solid tumors and other major diseases. Listat's internalizing RGD, or Arginy(g)vy/aspartic acid, (IRGD) cyclic peptide product candid <u>contending</u>, is an investigational drug designed to advate a novel uptake pathway that allows co-administered or tethered and-cancer drugs to selectively target and penetrate solid tumors more effectively. Listat has already established noteworthy commercial and R&D partnerships based on its <u>CandR Platform@</u>; <u>technology</u>. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about <u>certeptide's mechanism of action in our s</u> <u>film</u>. For more information on the Company, please with <u>www.listat.com</u>. of action in our short

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology companies, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Immunology, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughAwards.com

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

Forward-Looking Statements

This communication contains "forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding the Company's clinical development (roggers are forward-looking statements). In addition, when or if used in this communication, the words "may," could, "should, "anticipate, "believe," restimate, "expect," rintend." "pilon," product and similar expressions and their variants, as they relate to Lisata or a transagement, may identify forward-looking statements. Examples of forward-looking statements is used to clicas: the appropriate produce to Lisata, the appropriate private clicas: the appropriate private private clicas: the appropriate private private private as a result of the clicas traits approace private private approace private private private as a result of the clicas traits approace private pr

Lisata Therapeutics Contact:

Investors:

Intrestors. Listata Therapeutics John Menditto Vice President, Investor Relations and Corporate Communications Phone: 908-842-0084 Email: jmenditto@lisata.com

Media: ICR Healthcare Elizabeth Coleman Senior Associate Phone: 203-682-4783 Email: elizabeth.coleman@westwicke.com

A photo accompanying this announcement is available at https://www.globene wire.com/NewsRoom/AttachmentNg/0b47bc4c-3623-4fae-ba86-6addc8b e007b